WallStreetZenWallStreetZen

NASDAQ: CCCC
C4 Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CCCC stock forecasts and price targets.

Forecast return on equity

Is CCCC forecast to generate an efficient return?

Company
24.02%
Industry
161.35%
Market
89.43%
CCCC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CCCC forecast to generate an efficient return on assets?

Company
14.67%
Industry
42.65%
CCCC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CCCC earnings per share forecast

What is CCCC's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.61
Avg 2 year Forecast
-$1.53
Avg 3 year Forecast
-$1.36

CCCC revenue forecast

What is CCCC's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$22.5M-43.45%
Avg 2 year Forecast
$28.9M-27.36%
Avg 3 year Forecast
$25.2M-36.76%
CCCC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CCCC revenue growth forecast

How is CCCC forecast to perform vs Biotechnology companies and vs the US market?

Company
-12.21%
Industry
55.82%
Market
10.32%
CCCC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CCCC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CCCC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CCCC$1.71N/AN/A
KYTX$2.82$12.50+343.26%Strong Buy
CSBR$8.82$12.00+36.05%Buy
ACTU$6.24$20.00+220.51%Buy
MIST$2.25$7.50+233.33%Buy
View Top Biotech Stocks

C4 Therapeutics Stock Forecast FAQ

What is CCCC's earnings growth forecast for 2025-2027?

(NASDAQ: CCCC) C4 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.79%.

C4 Therapeutics's earnings in 2025 is -$103,277,000.On average, 5 Wall Street analysts forecast CCCC's earnings for 2025 to be -$114,463,418, with the lowest CCCC earnings forecast at -$127,102,679, and the highest CCCC earnings forecast at -$107,930,766. On average, 5 Wall Street analysts forecast CCCC's earnings for 2026 to be -$108,356,809, with the lowest CCCC earnings forecast at -$156,215,583, and the highest CCCC earnings forecast at -$78,107,791.

In 2027, CCCC is forecast to generate -$96,569,633 in earnings, with the lowest earnings forecast at -$164,736,433 and the highest earnings forecast at -$46,864,675.

If you're new to stock investing, here's how to buy C4 Therapeutics stock.

What is CCCC's revenue growth forecast for 2025-2027?

(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of -12.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.

C4 Therapeutics's revenue in 2025 is $39,783,000.On average, 4 Wall Street analysts forecast CCCC's revenue for 2025 to be $1,597,375,339, with the lowest CCCC revenue forecast at $514,091,281, and the highest CCCC revenue forecast at $2,577,557,113. On average, 3 Wall Street analysts forecast CCCC's revenue for 2026 to be $2,051,962,685, with the lowest CCCC revenue forecast at $1,206,836,383, and the highest CCCC revenue forecast at $2,840,283,320.

In 2027, CCCC is forecast to generate $1,786,325,187 in revenue, with the lowest revenue forecast at $764,888,298 and the highest revenue forecast at $2,485,247,905.

What is CCCC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CCCC) forecast ROA is 14.67%, which is lower than the forecast US Biotechnology industry average of 42.65%.

What is CCCC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CCCC) C4 Therapeutics's current Earnings Per Share (EPS) is -$1.47. On average, analysts forecast that CCCC's EPS will be -$1.61 for 2025, with the lowest EPS forecast at -$1.79, and the highest EPS forecast at -$1.52. On average, analysts forecast that CCCC's EPS will be -$1.53 for 2026, with the lowest EPS forecast at -$2.20, and the highest EPS forecast at -$1.10. In 2027, CCCC's EPS is forecast to hit -$1.36 (min: -$2.32, max: -$0.66).

What is CCCC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CCCC) forecast ROE is 24.02%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.